Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.16
-1.58 (-8.00%)
At close: Mar 27, 2026, 4:00 PM EDT
18.52
+0.36 (1.98%)
After-hours: Mar 27, 2026, 7:31 PM EDT
Denali Therapeutics Employees
Denali Therapeutics had 503 employees as of December 31, 2025. The number of employees increased by 81 or 19.19% compared to the previous year.
Employees
503
Change
81
Growth
19.19%
Revenue / Employee
n/a
Profits / Employee
-$1,018,966
Market Cap
2.88B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 503 | 81 | 19.19% |
| Sep 30, 2025 | 517 | 127 | 32.56% |
| Jun 30, 2025 | 486 | 122 | 33.52% |
| Mar 31, 2025 | 443 | 68 | 18.13% |
| Dec 31, 2024 | 422 | -23 | -5.17% |
| Sep 30, 2024 | 390 | -57 | -12.75% |
| Jun 30, 2024 | 364 | -74 | -16.89% |
| Mar 31, 2024 | 375 | -55 | -12.79% |
| Dec 31, 2023 | 445 | 18 | 4.22% |
| Sep 30, 2023 | 447 | 34 | 8.23% |
| Jun 30, 2023 | 438 | 43 | 10.89% |
| Mar 31, 2023 | 430 | 50 | 13.16% |
| Dec 31, 2022 | 427 | 47 | 12.37% |
| Sep 30, 2022 | 413 | 53 | 14.72% |
| Jun 30, 2022 | 395 | 61 | 18.26% |
| Mar 31, 2022 | 380 | 69 | 22.19% |
| Dec 31, 2021 | 380 | 89 | 30.58% |
| Sep 30, 2021 | 360 | 79 | 28.11% |
| Jun 30, 2021 | 334 | 58 | 21.01% |
| Mar 31, 2021 | 311 | 50 | 19.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Viridian Therapeutics | 252 |
| Vera Therapeutics | 249 |
| Alumis | 224 |
DNLI News
- 2 days ago - Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript - Seeking Alpha
- 3 days ago - Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - GlobeNewsWire
- 8 days ago - Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript - Seeking Alpha
- 22 days ago - Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 22 days ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 4 weeks ago - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 weeks ago - Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 weeks ago - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™ - GlobeNewsWire